Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
{{output}}
Background: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable. ... ...
